Analysis of outcome indexes in randomized controlled trials of traditional Chinese medicine for rheumatic heart disease.
10.19540/j.cnki.cjcmm.20210922.502
- Author:
Xiao-di SHENG
1
;
Chao CHEN
2
;
Ting ZHANG
1
;
Hai-Yin HU
1
;
Zhao-Chen JI
1
;
Bo-Han NIU
1
;
Ming-Yan ZHANG
1
;
Dong ZHANG
1
;
Li-Ping GUO
3
;
Hui WANG
1
;
Jun-Hua ZHANG
1
Author Information
1. Center for Evidence-based Medicine, Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.
2. First Teaching Hospital of Tianjin University of Traditional Chinese Medicine Tianjin 300193, China.
3. Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital Tianjin 300120, China.
- Publication Type:Review
- Keywords:
core outcome set;
outcome index;
randomized controlled trial;
rheumatic heart disease;
traditional Chinese medicine
- MeSH:
Drugs, Chinese Herbal/therapeutic use*;
Humans;
Medicine, Chinese Traditional;
Quality of Life;
Randomized Controlled Trials as Topic;
Rheumatic Heart Disease/drug therapy*;
Treatment Outcome
- From:
China Journal of Chinese Materia Medica
2022;47(1):244-252
- CountryChina
- Language:Chinese
-
Abstract:
The present study analyzed the efficacy evaluation indexes of the randomized controlled trials(RCTs) of Chinese medi-cine in the treatment of rheumatic heart disease to lay the foundation for the construction of the corresponding core outcome index set. Clinical RCTs with a definite diagnosis of rheumatic heart disease were retrieved from CNKI, Wanfang, VIP, Sino Med, Pub Med, EMbase, and Cochrane Library from January 1, 2010, to December 31, 2020. Thirty-five RCTs were included, involving 3 314 patients and 41 efficacy evaluation indexes, which covered seven domains [traditional Chinese medicine(TCM) symptoms/syndromes, symp-toms/signs, physical and chemical examination, quality of life, long-term prognosis, economic evaluation, and safety events]. Physi-cal and chemical examination(56. 91%) and symptoms/signs(29. 27%) were the more frequently applied. The number of indexes used in a single trial ranged from 1 to 15, with an average of 4. The measurement time points of the top five indexes in the frequency of use were as follows: total response rate was reported at five measurement time points, ranging from 14 days to 6 months; left ventri-cular ejection fraction was measured at eight time points ranging from 5 days to 6 months; left ventricular end systolic diameter was measured at six time points, ranging from 5 days to 6 months; interleukin-2(IL-2) and tumor necrosis factor-α(TNF-α) were repor-ted 28 days after treatment. At present, there are many problems in the efficacy outcome indexes of RCTs in the treatment of rheumatic heart disease with TCM, such as large difference in quantity, unclear primary and secondary indexes, unreasonable selection of " surro-gate indexes", insufficient attention to long-term prognostic indexes and safety event indexes, non-standard application of composite in-dexes, long measurement period, and lack of TCM characteristics. It is urgent to establish the core outcome set for TCM treatment of rheumatic heart disease.
